ALRN (Aileron Therapeutics, Inc.) Enterprise Value-to-Revenue Coefficient

Official company branding of Aileron Therapeutics (ALRN)

Aileron Therapeutics (ALRN) is developing innovative tissue protection agents for cancer therapy based on unique protein inhibition. The EV/Sales trend reflects the market's reaction to asset risk, where the 0.00 mark serves as the current indicator. The monetization of peptide platforms is building long-term capital, while orphan drug status within a narrow oncological niche minimizes competitive pressure.

Aileron Therapeutics Inc (ALRN): EV/Sales Multiple from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Aileron (ALRN)

- business market valuation indicators:
- cash balance and cash flow data:
Fundamental company valuation:Aileron Therapeutics Inc ALRN
Product sample of Aileron Therapeutics Inc

The robotization of laboratory oncology tests accelerates peptide discovery, directly impacting the revenue scaling potential of Aileron Therapeutics (ALRN). By analyzing EV/Sales dynamics, an investor assesses the total enterprise value relative to sales volumes, which allows for the tracking of multiple compression under the pressure of inflationary costs and the timely adjustment of the asset's portfolio weight.